摘要
Abstract
Objective To evaluate the prognostic predictive capability of a risk scoring model based on allograft rejection-related genes(ARRGS)in patients with hepatocellular carcinoma(HCC)and to validate the expression levels of the key gene Glomulin(GLMN)in HCC.Methods Expression data for HCC were downloaded from The Cancer Genome Atlas(TCGA)database,and ARRGS gene sets were obtained from the Misgdb database to construct ARRGS-related molecular subtypes.A prognostic model was developed using Lasso-Cox regression analysis,and its predictive performance was assessed through Kaplan-Meier survival analysis,time-dependent ROC curves,and internal validation.Twelve pairs of HCC tumor and adjacent non-tumor tissues were collected from patients who underwent radical surgery at Fuyang Minsheng Hospital between January 2020 and December 2023.The expression levels of GLMN in these samples were validated using Western blot(WB),real-time quantitative PCR(RT-qPCR)and immunohisto chemistry(IHC).Additionally,the correlation between GLMN expression and alpha-fetoprotein(AFP)levels in HCC patients were analyzed.Results Two molecular subtypes were identified based on ARRGS,with Cluster 1 demonstrating poorer prognosis and higher levels of immune infiltration.A prognostic model was constructed using ARRGS-related differentially expressed genes,including DYRK3,GLMN,MRPL3 and NME1,which exhibited robust predictive performance for 1-,3-and 5-year patient survival.In clinical samples,GLMN protein(t=4.275,P=0.023)and mRNA(t=8.313,P=0.003)levels were significantly elevated in tumor tissues,as confirmed by WB and RT-qPCR,and were strongly correlated with elevated AFP levels(r=0.688,P=0.028).Conclusion The ARRGS-based risk scoring model effectively predicts the prognosis of HCC patients.Elevated GLMN expression in HCC tumor tissues suggests its potential as a reliable diagnostic biomarker for HCC.关键词
肝细胞癌/风险评分模型/同种异体移植排斥相关基因/血管球蛋白Key words
hepatocellular carcinoma/risk scoring model/allograft rajection related genes/glomulin分类
医药卫生
